Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
ACTIVE NOT RECRUITING
NCT07199504
PHASE2/PHASE3

A Self-Controlled Study on the Treatment of Restless Legs Syndrome in Uremia With Dipyridamole

Sponsor: Yunfeng Xia

View on ClinicalTrials.gov

Summary

The purpose of this clinical trial is to determine whether dipyridamole can treat restless legs syndrome in patients with uremia. In addition, the safety of dipyridamole will also be evaluated. The main questions this study aims to answer include: Can dipyridamole improve the symptoms of restless legs syndrome in participants? Can dipyridamole improve participants' anxiety, depression, sleep quality, and quality of life? What adverse reactions might participants experience while taking dipyridamole? This study is a self-controlled trial in which all participants receive active drug treatment. Participants will take dipyridamole daily (50 mg per dose, three times a day) for 6 months. The efficacy of dipyridamole will be evaluated by comparing relevant scale scores and laboratory indicators before and after treatment. In addition, adverse reactions during the treatment follow-up will be monitored to assess the safety of dipyridamole in this patient population.

Key Details

Gender

All

Age Range

18 Years - 75 Years

Study Type

INTERVENTIONAL

Enrollment

80

Start Date

2025-07-01

Completion Date

2026-12-31

Last Updated

2025-10-07

Healthy Volunteers

No

Interventions

DRUG

Dipyridamole 50mg tid

Participants will take dipyridamole daily (50mg each time, three times a day) for 6 months

Locations (1)

First Affiliated Hospital of Chongqing Medical University

Chongqing, Chongqing Municipality, China